• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Plasma Epstein-Barr virus DNA may have prognostic value for patients with nasopharyngeal carcinoma

byTeddy Guo
June 10, 2021
in StudyGraphics
Reading Time: 1 min read
0
Share on FacebookShare on Twitter

Click to read the study in Clinical Cancer Research.

RELATED REPORTS

Postoperative radioiodine ablation does not reduce cancer recurrence following thyroidectomy

#VisualAbstract: 3-Year Structured Exercise after Adjuvant Chemotherapy Improved Survival for Colon Cancer

#VisualAbstract: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

Tags: adjuvant chemotherapyclinical observationEpstein-Barr virusEpstein-Barr virus (EBV)head and neck cancernasopharyngealnasopharyngeal cancernasopharyngeal carcinomaplasma EBV (pEBV)plasma EBV DNAradiotherapy
Previous Post

#VisualAbstract: High-dose methylprednisolone vs. dexamethasone for COVID-19 pneumonia

 Next Post

#VisualAbstract Cutaneous reactions in children treated with MEK and/or BRAF inhibitors are common and often lead to interruptions or alterations in chemotherapy

RelatedReports

Selpercatinib may provide an effective response against RET-mutated thyroid cancer
Chronic Disease

Postoperative radioiodine ablation does not reduce cancer recurrence following thyroidectomy

July 31, 2025
#VisualAbstract: 3-Year Structured Exercise after Adjuvant Chemotherapy Improved Survival for Colon Cancer
StudyGraphics

#VisualAbstract: 3-Year Structured Exercise after Adjuvant Chemotherapy Improved Survival for Colon Cancer

August 7, 2025
#VisualAbstract: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
StudyGraphics

#VisualAbstract: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

July 9, 2025
#VisualAbstract: Adjuvant PD-1 Blockade With Camrelizumab Improves Survival in Nasopharyngeal Carcinoma
StudyGraphics

#VisualAbstract: Adjuvant PD-1 Blockade With Camrelizumab Improves Survival in Nasopharyngeal Carcinoma

March 26, 2025
Next Post
#VisualAbstract Cutaneous reactions in children treated with MEK and/or BRAF inhibitors are common and often lead to interruptions or alterations in chemotherapy

#VisualAbstract Cutaneous reactions in children treated with MEK and/or BRAF inhibitors are common and often lead to interruptions or alterations in chemotherapy

Ziltivekimab antagonism of IL-6 reduces inflammation and thrombosis in patients with atherosclerotic risk factors

Wellness Check: Mental Health

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Development of a Clinical Prediction Model for Anastomotic Leakage in Colorectal Surgery
  • Paclitaxel-coated devices do not reduce rates of major amputations in chronic limb-threatening ischemia
  • Effect of Intensive Blood Pressure Lowering Treatment on Retinal Microvasculature: Secondary Analysis From ESPRIT
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.